|
1
|
Fujimoto A, Totoki Y, Abe T, Boroevich KA,
Hosoda F, Nguyen HH, Aoki M, Hosono N, Kubo M, Miya F, et al:
Whole-genome sequencing of liver cancers identifies etiological
influences on mutation patterns and recurrent mutations in
chromatin regulators. Nat Genet. 44:760–764. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Dat VHX, Nhung BTH, Chau NNB, Cuong PH,
Hieu VD, Linh NTM and Quoc NB: Identification of potential microRNA
groups for the diagnosis of hepatocellular carcinoma (HCC) using
microarray datasets and bioinformatics tools. Heliyon.
8:e089872022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Guo Y, Ren Y, Dong X, Kan X and Zheng C:
An overview of hepatocellular carcinoma after insufficient
radiofrequency ablation. J Hepatocell Carcinoma. 9:343–355. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pfister D, Núñez NG, Pinyol R, Govaere O,
Pinter M, Szydlowska M, Gupta R, Qiu M, Deczkowska A, Weiner A, et
al: NASH limits anti-tumour surveillance in immunotherapy-treated
HCC. Nature. 592:450–456. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Steeg PS and Theodorescu D: Metastasis: A
therapeutic target for cancer. Nat Clin Pract Oncol. 5:206–219.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhang Y, Liang J, Cao N, Gao J, Xie Y,
Zhou S and Tang X: ASIC1α up-regulates MMP-2/9 expression to
enhance mobility and proliferation of liver cancer cells via the
PI3K/AKT/mTOR pathway. BMC Cancer. 22:7782022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang C, Zhang H, Zhang L, Zhu AX, Bernards
R, Qin W and Wang C: Evolving therapeutic landscape of advanced
hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol.
20:203–222. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Llovet JM, Montal R, Sia D and Finn RS:
Molecular therapies and precision medicine for hepatocellular
carcinoma. Nat Rev Clin Oncol. 15:599–616. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu Z, Lin Y, Zhang J, Zhang Y, Li Y, Liu
Z, Li Q, Luo M, Liang R and Ye J: Molecular targeted and immune
checkpoint therapy for advanced hepatocellular carcinoma. J Exp
Clin Cancer Res. 38:4472019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Faivre S, Rimassa L and Finn RS: Molecular
therapies for HCC: Looking outside the box. J Hepatol. 72:342–352.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Huang A, Yang XR, Chung WY, Dennison AR
and Zhou J: Targeted therapy for hepatocellular carcinoma. Signal
Transduct Target Ther. 5:1462020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lanaya H, Natarajan A, Komposch K, Li L,
Amberg N, Chen L, Wculek SK, Hammer M, Zenz R, Peck-Radosavljevic
M, et al: EGFR has a tumour-promoting role in liver macrophages
during hepatocellular carcinoma formation. Nat Cell Biol.
16:972–977. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang Z: ErbB Receptors and Cancer. Methods
Mol Biol. 1652:3–35. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Thompson SM, Jondal DE, Butters KA,
Knudsen BE, Anderson JL, Stokes MP, Jia X, Grande JP, Roberts LR,
Callstrom MR and Woodrum DA: Heat stress induced,
ligand-independent MET and EGFR signalling in hepatocellular
carcinoma. Int J Hyperthermia. 34:812–823. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Reynolds AR, Tischer C, Verveer PJ, Rocks
O and Bastiaens PI: EGFR activation coupled to inhibition of
tyrosine phosphatases causes lateral signal propagation. Nat Cell
Biol. 5:447–453. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Niu J, Li W, Liang C, Wang X, Yao X, Yang
RH, Zhang ZS, Liu HF, Liu FY, Pei SH, et al: EGF promotes DKK1
transcription in hepatocellular carcinoma by enhancing the
phosphorylation and acetylation of histone H3. Sci Signal.
13:eabb57272020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ma Y, Xu R, Liu X, Zhang Y, Song L, Cai S,
Zhou S, Xie Y, Li A, Cao W and Tang X: LY3214996 relieves acquired
resistance to sorafenib in hepatocellular carcinoma cells. Int J
Med Sci. 18:1456–1464. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Krebs AM, Mitschke J, Lasierra Losada M,
Schmalhofer O, Boerries M, Busch H, Boettcher M, Mougiakakos D,
Reichardt W, Bronsert P, et al: The EMT-activator Zeb1 is a key
factor for cell plasticity and promotes metastasis in pancreatic
cancer. Nat Cell Biol. 19:518–529. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kudo-Saito C, Shirako H, Takeuchi T and
Kawakami Y: Cancer metastasis is accelerated through
immunosuppression during Snail-induced EMT of cancer cells. Cancer
Cell. 15:195–206. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang WH, Lan HY, Huang CH, Tai SK, Tzeng
CH, Kao SY, Wu KJ, Hung MC and Yang MH: RAC1 activation mediates
Twist1-induced cancer cell migration. Nat Cell Biol. 14:366–374.
2012. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yeh HW, Hsu EC, Lee SS, Lang YD, Lin YC,
Chang CY, Lee SY, Gu DL, Shih JH, Ho CM, et al: PSPC1 mediates
TGF-β1 autocrine signalling and Smad2/3 target switching to promote
EMT, stemness and metastasis. Nat Cell Biol. 20:479–491. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gonzalez DM and Medici D: Signaling
mechanisms of the epithelial-mesenchymal transition. Sci Signal.
7:re82014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Puisieux A, Brabletz T and Caramel J:
Oncogenic roles of EMT-inducing transcription factors. Nat Cell
Biol. 16:488–494. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lin J, Song T, Li C and Mao W: GSK-3β in
DNA repair, apoptosis, and resistance of chemotherapy, radiotherapy
of cancer. Biochim Biophys Acta Mol Cell Res. 1867:1186592020.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pecoraro C, Faggion B, Balboni B, Carbone
D, Peters GJ, Diana P, Assaraf YG and Giovannetti E: GSK3β as a
novel promising target to overcome chemoresistance in pancreatic
cancer. Drug Resist Updat. 58:1007792021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lv Q, Wang J, Xu C, Huang X, Ruan Z and
Dai Y: Pirfenidone alleviates pulmonary fibrosis in vitro and in
vivo through regulating Wnt/GSK-3β/β-catenin and TGF-β1/Smad2/3
signaling pathways. Mol Med. 26:492020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cano A, Pérez-Moreno MA, Rodrigo I,
Locascio A, Blanco MJ, del Barrio MG, Portillo F and Nieto MA: The
transcription factor snail controls epithelial-mesenchymal
transitions by repressing E-cadherin expression. Nat Cell Biol.
2:76–83. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Amin MB, Edge S, Greene F, Byrd DR,
Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR,
Sullivan DC, et al: AJCC Cancer Staging Manual. 8th edition.
Springer International Publishing; Cham, Switzerland: pp.
2912017
|
|
29
|
Liu X, Adorno-Cruz V, Chang YF, Jia Y,
Kawaguchi M, Dashzeveg NK, Taftaf R, Ramos EK, Schuster EJ,
El-Shennawy L, et al: EGFR inhibition blocks cancer stem cell
clustering and lung metastasis of triple negative breast cancer.
Theranostics. 11:6632–6643. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang Y, Cao N, Gao J, Liang J, Liang Y,
Xie Y, Zhou S and Tang X: ASIC1a stimulates the resistance of human
hepatocellular carcinoma by promoting EMT via the AKT/GSK3β/Snail
pathway driven by TGFβ/Smad signals. J Cell Mol Med. 26:2777–2792.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Babaei G, Aziz SG and Jaghi NZZ: EMT,
cancer stem cells and autophagy; The three main axes of metastasis.
Biomed Pharmacother. 133:1109092021. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Barrallo-Gimeno A and Nieto MA: The Snail
genes as inducers of cell movement and survival: Implications in
development and cancer. Development. 132:3151–3161. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Montanari M, Rossetti S, Cavaliere C,
D'Aniello C, Malzone MG, Vanacore D, Di Franco R, La Mantia E,
Iovane G, Piscitelli R, et al: Epithelial-mesenchymal transition in
prostate cancer: An overview. Oncotarget. 8:35376–35389. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Giannelli G, Koudelkova P, Dituri F and
Mikulits W: Role of epithelial to mesenchymal transition in
hepatocellular carcinoma. J Hepatol. 65:798–808. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Wang B, Liu T, Wu JC, Luo SZ, Chen R, Lu
LG and Xu MY: STAT3 aggravates TGF-β1-induced hepatic
epithelial-to-mesenchymal transition and migration. Biomed
Pharmacother. 98:214–221. 2018. View Article : Google Scholar : PubMed/NCBI
|
